Premium
Chronic Kidney Disease Progression to End Stage Renal Disease: A Single Center Experience of the Role of the Underlying Kidney Disease
Author(s) -
Ekart Robert,
Ferjuc Anita,
Furman Barbara,
Gerjevič Špela,
Bevc Sebastjan,
Hojs Radovan
Publication year - 2013
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.12079
Subject(s) - medicine , renal function , kidney disease , nephrology , end stage renal disease , proteinuria , renal replacement therapy , diabetic nephropathy , urology , nephropathy , gastroenterology , kidney , disease , endocrinology , diabetes mellitus
Chronic kidney disease ( CKD ) is common and several factors affect its progression to end‐stage renal disease ( ESRD ). The main goal of our study was to assess the influence of underlying kidney disease and some other important factors during the time of CKD progression to ESRD . A retrospective study of 91 patients (57 men, 34 women; average age 57.7 ± 13.2 years) was carried out. Patients were monitored at least one month before the first renal replacement treatment ( RRT ). Estimated glomerular filtration rate ( eGFR ) at first referral to nephrologist was determined by M odification of D iet in R enal D isease equation. Proteinuria was assessed semiquantitatively with dipsticks. Thirty‐five patients (38.5%) had diabetic nephropathy ( DN ), 21 (23.1%) hypertensive nephrosclerosis ( HN ), 21 (23.1%) adult polycystic kidney disease ( APKD ) and 14 (15.4%) immunoglobulin A nephropathy ( IgAN ). Average eGFR at first referral for DN patients was 20.1, and then 23.4 for HN , 35.5 for APKD , and 36.4 m L /min per 1,73 m 2 for IgAN patients. Average time between first nephrological visit and first RRT was 28.4 months for DN patients, 41 for HN , 80.8 for APKD , and 70.1 for IgAN patients. Comparison of all four groups of CKD patients showed that in patients with APKD and IgAN impairment of kidney function to ESRD had progressed statistically significantly slower ( P < 0.001). When eGFR at referral, proteinuria, smoking, and renin‐angiontensin‐aldosterone blockade treatment had been added into the model, patients with APKD and IgAN had a statistically significant longer period between first nephrological visit and first RRT ( P < 0.026). In comparison with patients with other underlying causes of CKD , patients with APKD and IgAN had a statistically significant slower progression rate of CKD to ESRD .